Markedly, the aPD-L1/I@LG + L group showed a 1.5- and 1.4-fold increase in tumor-infiltrating CD8+ T cells compared with the aPD-L1/I@LG-L and IR820@LG + L groups, respectively, indicating that the SMPAI strategy could amplify the T cells immune response and sensitize the immunotherapy of “cold” tumors with relatively low level of TILs. Here, CD8A is linked to neoplasm.